JP2019518022A5 - - Google Patents

Download PDF

Info

Publication number
JP2019518022A5
JP2019518022A5 JP2018562567A JP2018562567A JP2019518022A5 JP 2019518022 A5 JP2019518022 A5 JP 2019518022A5 JP 2018562567 A JP2018562567 A JP 2018562567A JP 2018562567 A JP2018562567 A JP 2018562567A JP 2019518022 A5 JP2019518022 A5 JP 2019518022A5
Authority
JP
Japan
Prior art keywords
compound
intrahepatic cholestasis
ceradelpar
amount
day
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018562567A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019518022A (ja
JP7079735B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/029620 external-priority patent/WO2017209865A1/en
Publication of JP2019518022A publication Critical patent/JP2019518022A/ja
Publication of JP2019518022A5 publication Critical patent/JP2019518022A5/ja
Application granted granted Critical
Publication of JP7079735B2 publication Critical patent/JP7079735B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018562567A 2016-05-31 2017-04-26 肝内胆汁うっ滞性疾患の処置 Active JP7079735B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662343688P 2016-05-31 2016-05-31
US62/343,688 2016-05-31
PCT/US2017/029620 WO2017209865A1 (en) 2016-05-31 2017-04-26 Treatment of intrahepatic cholestatic diseases

Publications (3)

Publication Number Publication Date
JP2019518022A JP2019518022A (ja) 2019-06-27
JP2019518022A5 true JP2019518022A5 (OSRAM) 2020-05-21
JP7079735B2 JP7079735B2 (ja) 2022-06-02

Family

ID=58699276

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018562567A Active JP7079735B2 (ja) 2016-05-31 2017-04-26 肝内胆汁うっ滞性疾患の処置

Country Status (27)

Country Link
US (5) US10272058B2 (OSRAM)
EP (1) EP3463328B1 (OSRAM)
JP (1) JP7079735B2 (OSRAM)
KR (1) KR102408288B1 (OSRAM)
CN (1) CN109195594A (OSRAM)
AU (1) AU2017274293B2 (OSRAM)
BR (1) BR112018074147A2 (OSRAM)
CA (1) CA3024155C (OSRAM)
CY (1) CY1125465T1 (OSRAM)
DK (1) DK3463328T3 (OSRAM)
ES (1) ES2921230T3 (OSRAM)
HR (1) HRP20220903T1 (OSRAM)
HU (1) HUE059838T2 (OSRAM)
IL (1) IL263372B2 (OSRAM)
LT (1) LT3463328T (OSRAM)
MX (1) MX390417B (OSRAM)
NZ (1) NZ748721A (OSRAM)
PL (1) PL3463328T3 (OSRAM)
PT (1) PT3463328T (OSRAM)
RS (1) RS63345B1 (OSRAM)
RU (1) RU2765460C2 (OSRAM)
SG (1) SG11201810123SA (OSRAM)
SI (1) SI3463328T1 (OSRAM)
SM (1) SMT202200471T1 (OSRAM)
UA (1) UA122719C2 (OSRAM)
WO (1) WO2017209865A1 (OSRAM)
ZA (1) ZA201808360B (OSRAM)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3119384T1 (sl) 2014-03-20 2018-12-31 Cymabay Therapeutics, Inc. Zdravljenje intrahepatičnih holestatičnih bolezni
US10272058B2 (en) 2014-03-20 2019-04-30 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
US10512622B2 (en) 2017-07-14 2019-12-24 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
KR20210092754A (ko) * 2018-11-16 2021-07-26 사이머베이 쎄라퓨틱스, 인코퍼레이티드 Nafld 및 nash의 병용 치료
CA3203235C (en) * 2021-02-01 2024-04-09 Yun-Jung Choi Treatment of cholangiopathies with seladelpar

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7101993B1 (en) 1990-01-11 2006-09-05 Isis Pharmaceuticals, Inc. Oligonucleotides containing 2′-O-modified purines
US7015315B1 (en) 1991-12-24 2006-03-21 Isis Pharmaceuticals, Inc. Gapped oligonucleotides
US5739135A (en) 1993-09-03 1998-04-14 Bristol-Myers Squibb Company Inhibitors of microsomal triglyceride transfer protein and method
EP0813539B1 (en) 1995-03-06 2006-05-24 Isis Pharmaceuticals, Inc. Improved process for the synthesis of 2'-o-substituted pyrimidines and oligomeric compounds therefrom
US6166197A (en) 1995-03-06 2000-12-26 Isis Pharmaceuticals, Inc. Oligomeric compounds having pyrimidine nucleotide (S) with 2'and 5 substitutions
ES2221039T3 (es) 1996-02-14 2004-12-16 Isis Pharmaceuticals, Inc. Oligonucleotidos abiertos modificados con azucar.
US5883109A (en) 1996-07-24 1999-03-16 Bristol-Myers Squibb Company Method for lowering serum lipid levels employing an MTP inhibitor in combination with another cholesterol lowering drug
US6066653A (en) 1997-01-17 2000-05-23 Bristol-Myers Squibb Co. Method of treating acid lipase deficiency diseases with an MTP inhibitor and cholesterol lowering drugs
US7407943B2 (en) 2001-08-01 2008-08-05 Isis Pharmaceuticals, Inc. Antisense modulation of apolipoprotein B expression
US7511131B2 (en) 2002-11-13 2009-03-31 Genzyme Corporation Antisense modulation of apolipoprotein B expression
US7981915B2 (en) 2003-04-30 2011-07-19 Beth Israel Deaconess Medical Center Methods for modulating PPAR biological activity for the treatment of diseases caused by mutations in the CFTR gene
ATE542793T1 (de) 2003-09-19 2012-02-15 Janssen Pharmaceutica Nv 4-((phenoxyalkyl)thio)-phenoxyessigsäuren und analoga
JP5697296B2 (ja) 2004-03-05 2015-04-08 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 高脂血症および高コレステロール血症に関連する障害または疾患を、副作用を最小限にしつつ処置するための方法
JO3006B1 (ar) 2005-09-14 2016-09-05 Janssen Pharmaceutica Nv املاح ليسين مبتكرة من مشتقات حامض 4-((فينوكسي الكيل)ثيو) فينوكسي الخليك
JP5694941B2 (ja) 2008-10-17 2015-04-01 シーマベイ セラピューティクス,インコーポレイティド 小型高密度ldl粒子を減少させる方法
MX2011011517A (es) * 2009-04-29 2012-06-19 Amarin Corp Plc Composiciones farmaceuticas que comprenden epa y un agente cardiovascular y metodos para utilizar el mismo.
MA34097B1 (fr) 2010-03-30 2013-03-05 Novartis Ag Utilisations d'inhibiteurs de dgat1
JOP20200043A1 (ar) 2011-05-10 2017-06-16 Amgen Inc طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
US20160279085A1 (en) 2013-11-20 2016-09-29 Cymabay Therapeutics, Inc. Treatment of Severe Hyperlipidemia
CN105764498A (zh) 2013-11-20 2016-07-13 西玛贝医药公司 纯合家族型高胆固醇血症的治疗
US10272058B2 (en) 2014-03-20 2019-04-30 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
SI3119384T1 (sl) 2014-03-20 2018-12-31 Cymabay Therapeutics, Inc. Zdravljenje intrahepatičnih holestatičnih bolezni
HRP20192299T1 (hr) 2014-04-11 2020-03-06 Cymabay Therapeutics, Inc. Liječenje nafld i nash
BR112016028918A2 (pt) 2014-06-26 2017-08-22 Cymabay Therapeutics Inc tratamento de hipertrigliceridemia grave
US10512622B2 (en) 2017-07-14 2019-12-24 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
EP3973959B8 (en) 2017-09-26 2025-01-15 CymaBay Therapeutics, Inc. Treatment of cholestatic pruritus with seladelpar
CA3118965A1 (en) 2018-11-16 2020-05-22 Cymabay Therapeutics, Inc. Treatment of obesity and its complications
KR20210092754A (ko) 2018-11-16 2021-07-26 사이머베이 쎄라퓨틱스, 인코퍼레이티드 Nafld 및 nash의 병용 치료

Similar Documents

Publication Publication Date Title
JP2019518022A5 (OSRAM)
JP2015083580A5 (OSRAM)
JP2019535760A5 (ja) ガボキサドールを用いた注意欠陥多動性障害(adhd)の治療方法
JP2017506624A5 (OSRAM)
JP2018162255A5 (OSRAM)
JP2015038135A5 (OSRAM)
JP2015187157A5 (OSRAM)
JP2016034978A5 (OSRAM)
JP2017508817A5 (OSRAM)
JP2020535225A5 (OSRAM)
JP2018527392A5 (OSRAM)
JP2015523407A5 (OSRAM)
JP2011173928A5 (OSRAM)
MX2018008021A (es) Metodos y composiciones para el tratamiento de trastornos relacionados con convulsiones.
JP2016185995A5 (OSRAM)
BR112014001297A2 (pt) procedimento para a fabricação de uma composição farmacêutica em forma de tabletes de liberação prolongada contendo pirfenidona e sua aplicação na regressão da insuficiência renal crônica, na contratura capsular mamária e na fibrose hepática humanas
JP2015522630A5 (OSRAM)
RU2014141893A (ru) Применение производной пиразола в лечении острых приступов хронической обструктивной болезни легких
JP2014198723A5 (OSRAM)
JP2015510916A5 (OSRAM)
JP2018530578A5 (OSRAM)
JP2017014206A5 (OSRAM)
JP2019218379A5 (OSRAM)
JP2013166781A5 (OSRAM)
JP2018172440A5 (OSRAM)